BioCentury
ARTICLE | Company News

Amplimmune, American National Multiple Sclerosis Society deal

August 31, 2009 7:00 AM UTC

The society's not-for-profit technology transfer subsidiary Fast Forward LLC will provide $500,000 in funding for preclinical development of Amplimmune's AMP-110 to prevent abnormal immune responses ...